Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aura Biosciences Inc ( (AURA) ) just unveiled an announcement.
On August 13, 2025, Aura Biosciences reported its second-quarter financial results and business highlights, emphasizing its ongoing clinical programs, including the Phase 3 CoMpass trial for early choroidal melanoma and the Phase 1b/2 trial for non-muscle invasive bladder cancer (NMIBC). The company strengthened its financial position with a $75 million equity financing, extending its cash runway into the first half of 2027. Aura is actively enrolling patients globally in its CoMpass trial and has received Orphan Drug and Fast Track designations from the FDA for early choroidal melanoma. Additionally, Aura is expanding its bel-sar development for metastases to the choroid and cancers of the ocular surface, with initial data expected in 2025 and 2026, respectively. The company’s financial results showed increased R&D expenses due to ongoing trials, while general and administrative expenses slightly decreased.
The most recent analyst rating on (AURA) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Aura Biosciences Inc stock, see the AURA Stock Forecast page.
Spark’s Take on AURA Stock
According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.
Aura Biosciences’ overall stock score reflects its early-stage biotech profile, characterized by no revenue, increasing losses, and negative cash flows. While the company maintains a solid balance sheet, its stock faces bearish technical indicators and speculative valuation. The recent board appointment is a positive development, but the company’s financial health and market trends remain the primary concerns.
To see Spark’s full report on AURA stock, click here.
More about Aura Biosciences Inc
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Their lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma and in early-stage development for other ocular oncology indications and bladder cancer. The company is headquartered in Boston, MA.
Average Trading Volume: 208,427
Technical Sentiment Signal: Sell
Current Market Cap: $430.3M
For a thorough assessment of AURA stock, go to TipRanks’ Stock Analysis page.